Updated:
Clal Biotechnology
Clal Biotechnology Industries (TASE: CBI) is a premier life sciences investment firm listed on the Tel Aviv Stock Exchange. It specializes in identifying and...
Clal Biotechnology
Clal Biotechnology Industries (TASE: CBI) is a premier life sciences investment firm listed on the Tel Aviv Stock Exchange. It specializes in identifying and nurturing groundbreaking ventures that develop proprietary solutions to address unmet medical needs with substantial market potential. CBI holds and manages an international portfolio of some thirteen biotechnology companies.
General information
Firm type
Private Equity
Year founded
1993
Location
Region
Middle East
Country
Israel
City
Tel Aviv
Corporate office
Tel Aviv, Israel
Principals
Avi Fischer
CEO
Arnon Aharon
MD, Medical Director
Liat Nissan
CFO
Avi Fischer
Chairman of the Board
Prof. Gad Keren
Board Member
Bazil Gamzu
Board Member
Nufar Malovani
Board Member
Prof. Gabi Barabash
Board Member
Tomer Babai
Board Member
Sector focus
Frequently asked questions
What stages does Clal Biotechnology target?
The firm covers seed, start-up, and expansion rounds within its venture and private equity practice.
Does Clal Biotechnology commit to external funds or make direct investments?
Available records indicate direct investment activity without reference to fund commitments or fund-of-funds structures.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: